Today: March 22, 2018, 12:57 pm

Biocartis Group NV: Disclosure of a transparency notification 2017-11-14 07:02:01


14 November 2017, 07:00 CET

Disclosure of a transparency notification

(Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings)

Mechelen, Belgium, 14 November 2017 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that it received a transparency notification dated 10 November 2017 (the 'Notification'), indicating that as a result of the disposal of voting securities on 7 November 2017, TopBio1 LP crossed the lowest notification threshold of 3%. As a result, TopBio1 LP no longer holds voting securities or voting rights in Biocartis.

The Notification contains the following information:


·         Reason for the Notification: Downward crossing of the lowest threshold. Acquisition or disposal of voting securities or voting rights.


·         Notification by: A person that notifies alone.


·         Persons subject to the notification requirement: TopBio1 LP, 89 Nexus Way, 2nd Floor, Camana Bay, P.O. Box 31106, Grand Cayman, KY1-1205 Cayman Islands.


·         Transaction date: 7 November 2017.


·         Threshold that is crossed: 3%.


·         Denominator: 44,669,772.


·         Details of the Notification: TopBio1 LP no longer holds voting securities or voting rights in Biocartis.


·         Chain of controlled undertakings through which the holding was effectively being held: TopBio1 LP is not a controlled entity.


The Notification is available here on the website of the Company.

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority ('FSMA') is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

----- END ----

More information:
Renate Degrave
Manager Corporate Communications & Investor Relations Biocartis
tel +32 15 631 729 | mobile +32 471 53 60 64 

About Biocartis 

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers ten oncology tests and two infectious disease tests in Europe. More information: Press Photo Library available here. Follow us on Twitter: @Biocartis_.

The Biocartis trademark and logo are trademarks of Biocartis and are used and registered in Europe. Idylla(TM) is a registered trademark in the United States and other countries. The Idylla(TM) trademark and logo are trademarks of and used by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release. You should not place undue reliance on forward-looking statements.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biocartis Group NV via Globenewswire

# 1134 Words
Related Articles
More From The Author
Graphus Launches Office in India to Drive [..]
Graphus Inc., a leading cloud applications cybersecurity company, announced today they have incorporated a subsidiary company and [..]
Publicis Groupe salutes Cannes Lions Festival's initiative [..]
Publicis Groupe salutes Cannes Lions Festival's initiative and reconfirms its participation from 2019 onwards In 2018, Publicis [..]
RedHill Biopharma Announces Closing of Public Offering [..]
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) [..]
Citi Successfully Pilots New Digital Platform to [..]
Citi (NYSE: C) announced today the successful pilot of a new digital proxy voting platform, ProxymitySM, which directly connects [..]
Concurrent Files Definitive Proxy Statement for Proposed [..]
  ATLANTA, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Concurrent (NASDAQ:CCUR), a global leader in storage, protection, transformation, and [..]
More From Business
RCBC Bankard launches new Platinum card with [..]
Manila, Philippines and Tokyo, Japan, Mar 22, 2018 - (ACN Newswire) - JCB International Co., Ltd. (JCBI), the international operations [..]
Project Laneways Offers Change Management Courses in [..]
Project Laneways has announced it will be conducting change management courses in Canberra in May. The Change Management Foundation [..]
Jaguar Leaps Onto The SUV Bandwagon With [..]
When it came to jumping on the SUV bandwagon, it was inevitable that Jaguar would make the leap; after all, [..]
Bright Light Stocks Independent Control Systems for [..]
Through their website Bright Light provides a range of independent control systems that will provide both hardwired and wireless [..]
Easy, Convenient and Time-saving: Steam Cleaning Without [..]
Kärcher Steam Cleaners give you the experience of cleaning chemical-free, killing 99.99% of common household bacteria, santitise [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.